PDCD1 and hepatocellular carcinoma: To date, several distinct ICBs, including (1) the CTLA-4 antibody ipilimumab (Yervoy); (2) the PD-1 inhibitors: Cemiplimab (Libtayo), nivolumab (Opdivo), and pembrolizumab (Keytruda); and (3) the PD-L1 blockers: Atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi), have been approved to treat a variety of advanced cancers, including melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), and urothelial carcinoma.